COMMUNIQUÉS West-GlobeNewswire

CROSSJCROSSJECT annonce le succès d’une augmentation de capital et d’une émission de bons de souscription d’actions (BSA) au profit d’investisseurs pour un montant de 15 millions d’euros
22/05/2026
Nouveaux financements immédiats pour soutenir les prochaines étapes stratégiques de la Société Renforcement des capitaux propres et amélioration de la structure financière de la Société Soutient de la poursuite des [...]
Ex dividend NOK 1.00 today
22/05/2026
The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.00 as from today, 22.05.2026.
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
22/05/2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer Topline results to be presented by Alexandra Leary, MD, PhD, on May 30, 2026, at the 2026 Annual [...]
ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction
22/05/2026
LOS ANGELES, May 22, 2026 (GLOBE NEWSWIRE) -- ANGEL, a global water purification brand, has introduced the X2 Tankless RO Water Filter System, a compact under-sink solution designed to deliver fresh purified water while [...]
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
22/05/2026
Provides immediate new financing to support the Company’s next strategic milestones Strengthens shareholders’ equity and improves the Company’s financial structure Supports the continuation of ZEPIZURE® regulatory [...]
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
22/05/2026
VANCOUVER, British Columbia, May 21, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative [...]
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
22/05/2026
NORTHFIELD, Ill., May 21, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its upsized secondary offering of 72,554,594 shares of Medline Inc.’s Class A common stock by [...]
FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed
22/05/2026
FemiCore Ingredients Explained: Mimosa Pudica, Cranberry, Bearberry, Berberine, and 5-Strain Lactobacillus Probiotic Blend for Women's Bladder Support in 2026 Tallmadge, Ohio, May 21, 2026 (GLOBE NEWSWIRE) -- These [...]
Most Effective Magnesium Pain Cream Researched: Real Magnesium Niacinamide Relief for Peak Health & Nerve Pain Recovery
22/05/2026
How the Magnesium Chloride and Niacinamide Topical Cream with Arnica, Boswellia, Menthol, and Camphor Supports Joint, Nerve, and Muscle Comfort Routines SPEARFISH, SD, May 21, 2026 (GLOBE NEWSWIRE) -- These statements [...]
Liminatus Pharma Announces Nasdaq Delisting Notification
22/05/2026
FULLERTON, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company received a delisting notice from The Nasdaq Stock Market LLC (“ [...]
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 [...]
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026
The Phase 2b LUMA study of BIIB122 in early-stage Parkinson’s disease did not meet its primary or secondary endpoints Based on data from the Phase 2b LUMA study, Biogen and Denali will discontinue development of BIIB122 [...]
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
22/05/2026
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered [...]
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
22/05/2026
ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the [...]
Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting
22/05/2026
~ Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK ® (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations ~ ~ Real-World Evidence Shows [...]
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study
22/05/2026
Last Patient In enrolled ahead of schedule; interim analysis anticipated by year-end 2026 to inform plans for the next stage of development TAIPEI, May 21, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) today [...]
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
21/05/2026
SAN DIEGO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeutics, Inc. (Nasdaq: TRAX), a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in [...]
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
21/05/2026
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across multiple solid tumor [...]
Lunavelle Sleep Patches Claims Evaluated: Most Effective Melatonin-Free Patches for Deeper Rest with Time-Tested Ingredients Proven To Work
21/05/2026
Lunavelle Sleep Patches Research, Ingredients, Side Effects, and Refund Policy Explained: Magnesium Glycinate, L-Theanine, GABA, and Valerian Root Formula San Francisco, CA, May 21, 2026 (GLOBE NEWSWIRE) -- These [...]

Pages